A Phase 2/3 interventional study of Placebo and Upadacitinib in Ulcerative Colitis (UC), sponsored by AbbVie. Completed at 496 sites in 46 countries. Open to participants aged 16 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-06-30.
Sponsored by AbbVie · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing upadacitinib in Colitis, Ulcerative — 8 open to participants now, 10 under way, 3 of them phase 3. upadacitinib · Colitis, Ulcerative.
Among the 12 studies testing upadacitinib in Colitis, Ulcerative, this one has the largest enrollment, is the only one that started in 2016, is the only one in phase 2/3, and was the 1st registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →8 of the 12 studies testing upadacitinib in Colitis, Ulcerative are open now, in 3 countries. Recruiting first, the newest first:
Xijing Hospital of Digestive Diseases · Sites in China
Ages 18–85
Yongquan Shi · Sites in China
Ages 18–85
Berinstein, Jeffrey · Sites in United States
Ages 18–75
McMaster University · Sites in Canada
Ages 18–64
Sixth Affiliated Hospital, Sun Yat-sen University · Sites in China
Ages 18+
By country, each count listing its studies:
upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 16 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 5 · Phase 4 6
First in 2016; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,302 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 180 across the 12 interventional studies. Of the 2 that completed or were terminated, 2 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 12 have an industry lead sponsor. The 8 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
53 studies in Colitis, Ulcerative by AbbVie: 6 open now, 13 under way, 5 of them phase 3. Of 36 finished, 22 (61%) have results posted.
Among the 53 studies in Colitis, Ulcerative by AbbVie, this one is the 3rd largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2016, is one of 2 in phase 2/3, and was the 24th registered.
AbbVie’s Colitis, Ulcerative studies by the year they started, since 2000.
4 of the studies testing upadacitinib in Colitis, Ulcerative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06660693Phase 3McMaster UniversityComparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis | 2027-05 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT07546097Yongquan ShiComparative Effectiveness of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis(UPFRONT) | 2027-03-30 |
| NCT05867329Berinstein, JeffreyFeasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis | 2027-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 12 studies testing upadacitinib in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 53 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
This study was comprised of three substudies. The objective of Substudy 1 was to characterize the dose-response, efficacy, and safety of upadacitinib compared to placebo in inducing clinical remission to identify the induction dose of upadacitinib for further evaluation in Substudy 2. The objective of Substudy 2 was to evaluate the efficacy and safety of upadacitinib compared to placebo in inducing clinical remission in participants. The objective of Substudy 3 was to evaluate the efficacy and safety of upadacitinib compared to placebo in achieving clinical remission in participants who had a response following induction with upadacitinib.
Substudy 1 was a Phase 2b dose-ranging study designed to evaluate the efficacy and safety of different oral doses of upadacitinib compared to placebo as 8-week induction therapy in participants with moderately to severely active UC. Approximately 250 participants were planned to be randomized 1:1:1:1:1 to the placebo group and 4 upadacitinib doses (7.5, 15, 30, and 45 mg). Randomization was stratified by previous biologic therapy use (yes/no), Baseline corticosteroid use (yes/no), and Baseline Adapted Mayo score (≤ 7 or > 7). The study duration included a Screening Period of up to 5 weeks and an 8-week double-blind (DB) Induction Period. After all randomized participants completed the 8-week induction, a dose-selection analysis of efficacy and safety (selected laboratory parameters) of upadacitinib versus placebo was performed. Based on this dose-selection analysis, one induction dose (upadacitinib 45 mg) was identified for further evaluation in two Phase 3 induction studies, M14-234 Substudy 2 and M14-675 (NCT03653026). During the analysis period, 132 additional participants were randomized into Groups 3 and 4 of Substudy 1 (upadacitinib 30 mg and 45 mg dose groups; approximately 66 participants per dose group). The objectives of enrolling these additional participants were to avoid interrupting the study activities during the analysis period and to support a sufficient number of participants with clinical response to be re-randomized into the maintenance portion in Substudy 3. Substudy 1 main participants are defined as those first 250 randomized 250, and additional participants are defined as those who were randomized after the main participants.
Substudy 2 was a two-part Phase 3 dose-confirming study designed to evaluate the efficacy and safety of oral administration of upadacitinib 45 mg compared to placebo as induction therapy for up to 16 weeks in participants with moderately to severely active UC. Substudy 2 included a Screening Period of up to 5 weeks, Part 1, and Part 2. Part 1 was a randomized, DB, placebo-controlled 8-week induction period. Part 2 was an open-label, 8-week extended treatment period for clinical non-responders from Part 1 of Substudy 2. Part 1 was planned to enroll 462 subjects; actual enrollment was 474 subjects. Eligible participants were randomized in a 2:1 ratio to one of the two treatment groups (DB upadacitinib 45 mg or matching placebo) for 8 weeks. The randomization was stratified by bio-IR status (Biologic inadequate responders [bio-IR] vs Non-biologic-inadequate responders [non-bio-IR], corticosteroid use (yes or no), and Adapted Mayo score (≤ 7 or > 7) at Baseline. Within bio-IR, the randomization was further stratified by number of prior biologic treatments (≤ 1 or > 1). Within non-bio-IR, the randomization was further stratified by previous biologic use (yes or no). Part 2 was an open label, 8-week Extended Treatment Period for those who did not achieve clinical response per Adapted Mayo score at Week 8 in Part 1. All participants received upadacitinib 45 mg.
Substudy 3 was a Phase 3 maintenance study designed to evaluate the efficacy and safety of upadacitinib 15 and 30 mg once daily (QD) compared to placebo in achieving clinical remission per Adapted Mayo score in participants with moderately to severely active UC who achieved clinical response per Adapted Mayo score following induction therapy from Substudy 1, Substudy 2, or Study M14-675. A total of 1,046 subjects who achieved clinical response per Adapted Mayo score after completion of induction treatment or Extended Treatment Period in Study M14-234 Substudy 1, Substudy 2, or Study M14-675 entered Substudy 3, and 1,044 were treated with a blinded treatment assignment for up to 52 weeks. Substudy 3 included 4 cohorts. Cohort 1: 847 participants who achieved clinical response in Substudy 1, Substudy 2, or Study M14-675 at either Week 8 or Week 16, and received upadacitinib 15, 30, or 45 mg QD. The treatment groups in Cohort 1 were Group 1: upadacitinib 15 mg QD; Group 2: upadacitinib 30 mg QD; and Group 3: placebo QD. Those who achieved clinical response and received upadacitinib 15 mg QD in Substudy 1 were re-randomized 1:1 to only receive upadacitinib 15 mg QD or placebo QD (treatment Group 1 or 3). Cohort 2: 104 participants who received double-blind placebo QD treatment for 8 weeks during Substudy 1, Substudy 2 Part 1, or Study M14-675 Part 1 and achieved clinical response at Week 8 continued to receive blinded placebo QD in Substudy 3. Cohort 3: 75 participants who received upadacitinib 45 mg QD in Induction Phase and did not achieve clinical response and received upadacitinib 45 mg QD in Extended Treatment in Substudy 2 Part 2 or in Study M14-675 Part 2 and achieved clinical response at Week 16 were re-randomized 1:1 and received blinded upadacitinib 30 mg QD or upadacitinib 15 mg QD in Substudy 3. Cohort 4: 20 participants who received double-blinded treatment of upadacitinib 7.5 mg QD for 8 weeks during Substudy 1 and achieved clinical response at Week 8 continued to receive blinded treatment of upadacitinib 7.5 mg QD in Substudy 3.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Note: Adolescent participants who are 16 or 17 years old will be eligible to participate if approved by the country or regulatory/health authority. If approval has not been granted, only participants ≥18 years old will be enrolled. Adolescents must weigh ≥ 40 kilograms and meet the definition of Tanner Stage 5 at Screening Visit.
Note: Participants who have had inadequate response, loss of response to conventional therapy, but have not failed biologic therapy (Non-bio-IR) and have received a prior biologic for up to 1 year may be enrolled, however they must have discontinued the biologic for reasons other than inadequate response or intolerance (e.g., change of insurance, well controlled disease) and must meet criteria for inadequate response, loss of response or intolerance to aminosalicylates, corticosteroids, and/or immunosuppressants as defined above.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During the 8-week induction phase in Substudy 1, participants received placebo for upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks.
Drug: Placebo
During the 8-week induction phase in Substudy 1, participants received 7.5 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks.
Drug: Upadacitinib
During the 8-week induction phase in Substudy 1, participants received 15 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks.
Drug: Upadacitinib
During the 8-week induction phase in Substudy 1, participants received 30 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks. Additional participants were enrolled during the Substudy 1 analysis period and received 30 mg upadacitinib film-coated tablets once daily by mouth (QD) for 4 weeks.
Drug: Upadacitinib
During the 8-week induction phase in Substudy 1, participants received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks. Additional participants were enrolled during the Substudy 1 analysis period and received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for 4 weeks.
Drug: Upadacitinib
During the Substudy 2 Part 1 induction period, participants received placebo for upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks. Participants who did not achieve clinical response at Week 8 of Part 1 were enrolled in an open-label extended treatment period and received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for an additional 8 weeks.
Drug: Placebo · Drug: Upadacitinib
During the Substudy 2 Part 1 induction period, participants received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks. Participants who did not achieve clinical response at Week 8 of Part 1 were enrolled in an open-label expended treatment period and received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for an additional 8 weeks.
Drug: Upadacitinib
Participants in Study M14-675 (NCT03653026) who achieved clinical response defined by Adapted Mayo Score at Week 8 or Week 16 in that study and did not meet any study discontinuation criteria were eligible to enroll into Substudy 3. Participants were re-randomized and treated with a blinded treatment assignment (15 mg upadacitinib film-coated tablets once daily by mouth \[QD\], or 30 mg upadacitinib film-coated tablets QD, or placebo for upadacitinib film-coated tablets QD) for up to 52 weeks.
Drug: Placebo · Drug: Upadacitinib
Film-coated tablet for oral administration
Film-coated tablet for oral administration
Also known as: ABT-494, RINVOQ
Substudy 1: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8
The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration) The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. For Substudy 1, clinical remission is defined as SFS ≤ 1, RBS of 0, and endoscopic subscore ≤ 1.
Time frame: At Week 8
Substudy 2: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8
The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration) The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. For Substudy 2, clinical remission is defined as SFS ≤ 1 and not greater than Baseline, RBS of 0, and endoscopic subscore ≤ 1. In Substudy 2, evidence of friability during endoscopy in participants with otherwise "mild" endoscopic activity conferred an endoscopic subscore of 2.
Time frame: At Week 8
Substudy 3: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 52
The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. For Substudy 3, clinical remission is defined as SFS ≤ 1 and not greater than Baseline, RBS of 0, and endoscopic subscore ≤ 1. In addition, evidence of friability during endoscopy in participants with otherwise "mild" endoscopic activity conferred an endoscopic subscore of 2.
Time frame: At Week 52
Substudy 1: Percentage Of Participants With Endoscopic Improvement at Week 8
Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
Time frame: At Week 8
Substudy 1: Percentage Of Participants Achieving Clinical Remission Per Full Mayo Score at Week 8
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The Full Mayo score (FMS) ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.
Time frame: At Week 8
Substudy 1: Percentage Of Participants Achieving Clinical Response Per Adapted Mayo Score at Week 8
The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. Clinical response is defined as a decrease from baseline in the Adapted Mayo score ≥ 2 points and ≥ 30% from baseline, and a decrease in RBS ≥ 1 or an absolute RBS ≤ 1).
Time frame: At Week 8
Substudy 1: Percentage Of Participants Achieving Clinical Response Per Partial Mayo Score at Week 2
The Partial Mayo Score is a composite score of UC disease activity based on the following 2 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). The overall Partial Mayo score ranges from 0 to 6 with higher scores representing more severe disease. Clinical response per Partial Mayo Score is defined as a decrease in Partial Adapted Mayo score ≥ 2 points and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.
Time frame: At Week 2
Substudy 1: Change in Full Mayo Score From Baseline to Week 8
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The Full Mayo score (FMS) ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.
Time frame: Baseline (Week 0), Week 8
Substudy 1: Percentage Of Participants With Endoscopic Remission at Week 8
Endoscopic remission is defined as an endoscopic subscore of 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
Time frame: At Week 8
Substudy 1: Percentage Of Participants Who Achieved Histologic Improvement at Week 8
The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration. Histologic improvement was defined as decrease from baseline in Geboes score.
Time frame: At Week 8
Substudy 2: Percentage Of Participants With Endoscopic Improvement at Week 8
Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
Time frame: At Week 8
Substudy 2: Percentage Of Participants With Endoscopic Remission at Week 8
Endoscopic remission is defined as an endoscopic subscore of 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
Time frame: At Week 8
Substudy 2: Percentage Of Participants Achieving Clinical Response Per Adapted Mayo Score at Week 8
The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. Clinical response is defined as a decrease from baseline in the Adapted Mayo score ≥ 2 points and ≥ 30% from baseline, and a decrease in RBS ≥ 1 or an absolute RBS ≤ 1).
Time frame: At Week 8
Substudy 2: Percentage Of Participants Achieving Clinical Response Per Partial Mayo Score at Week 2
The Partial Mayo Score is a composite score of UC disease activity based on the following 2 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). The overall Partial Mayo score ranges from 0 to 6 with higher scores representing more severe disease. Clinical response per Partial Mayo Score is defined as a decrease from Baseline ≥ 1 point and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.
Time frame: At Week 2
Substudy 2: Percentage Of Participants Who Achieved Histologic-Endoscopic Mucosal Improvement at Week 8
Histologic-endoscopic mucosal improvement is defined as an endoscopic subscore of 0 or 1 and a Geboes score ≤ 3.1. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.
Time frame: At Week 8
Substudy 2: Percentage Of Participants Who Report No Bowel Urgency at Week 8
Bowel urgency was assessed by participants in a subject diary completed once a day.
Time frame: At Week 8
Substudy 2: Percentage Of Participants Who Reported No Abdominal Pain at Week 8
Abdominal pain was assessed by participants in a subject diary completed once a day.
Time frame: At Week 8
Substudy 2: Percentage Of Participants Who Achieved Histologic Improvement at Week 8
The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration. Histologic improvement was defined as decrease from baseline in Geboes score.
Time frame: At Week 8
Substudy 2: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 8
The Inflammatory Bowel Disease Questionnaire (IBDQ) is used to assess health-related quality of life (HRQoL) in patients with ulcerative colitis. It consists of 32 questions evaluating bowel and systemic symptoms, as well as emotional and social functions. Each question is answered on a scale from 1 (worst) to 7 (best). The total score ranges from 32 to 224 with higher scores indicating better health-related quality of life. A positive change from Baseline indicates improvement.
Time frame: Baseline (Week 0), Week 8
Substudy 2: Percentage Of Participants With Mucosal Healing at Week 8
Mucosal healing is defined as an endoscopic score of 0 and Geboes score \< 2.0. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.
Time frame: At Week 8
Substudy 2: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 8
The FACIT fatigue questionnaire was developed to assess fatigue associated with anemia. It consists of 13 fatigue-related questions. Each question is answered on a 5-point Likert scale: 0 (not at all); 1 (a little bit); 2 (somewhat); 3 (quite a bit); and 4 (very much). The total score ranges from 0 to 52, where higher scores represent less fatigue, and a positive change from Baseline indicates improvement.
Time frame: Baseline (Week 0), Week 8
Substudy 3: Percentage Of Participants With Endoscopic Improvement at Week 52
Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
Time frame: At Week 52
Substudy 3: Percentage of Participants With Clinical Remission Per Adapted Mayo Score at Week 52 Among Those Who Achieved Clinical Remission at the End of the Induction Treatment
The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. For Substudy 3, clinical remission is defined as SFS ≤ 1 and not greater than Baseline, RBS of 0, and endoscopic subscore ≤ 1. In addition, evidence of friability during endoscopy in participants with otherwise "mild" endoscopic activity conferred an endoscopic subscore of 2.
Time frame: At Week 52
Substudy 3: Percentage of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Wk 52 and Were Corticosteroid Free for ≥ 90 Days Immediately Preceding Wk 52 Among Those Who Achieved Clinical Remission at the End of the Induction Treatment
The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. For Substudy 3, clinical remission is defined as SFS ≤ 1 and not greater than Baseline, RBS of 0, and endoscopic subscore ≤ 1. In addition, evidence of friability during endoscopy in participants with otherwise "mild" endoscopic activity conferred an endoscopic subscore of 2.
Time frame: At Week 52
Substudy 3: Percentage of Participants With Endoscopic Improvement at Wk 52 Among Those Who Achieved Endoscopic Improvement at the End of the Induction Treatment
Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
Time frame: At Week 52
Substudy 3: Percentage Of Participants With Endoscopic Remission At Week 52
Endoscopic remission is defined as an endoscopic subscore of 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
Time frame: At Week 52
Substudy 3: Percentage Of Participants Who Maintained Clinical Response Per Adapted Mayo Score at Wk 52 Among Those Who Achieved Clinical Response at the End of the Induction Treatment
The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. Clinical response is defined as a decrease from baseline in the Adapted Mayo score ≥ 2 points and ≥ 30% from baseline, and a decrease in RBS ≥ 1 or an absolute RBS ≤ 1).
Time frame: At Week 52
Substudy 3: Percentage Of Participants Who Achieved Histologic-Endoscopic Mucosal Improvement at Week 52
Histologic-endoscopic mucosal improvement is defined as an endoscopic subscore of 0 or 1 and a Geboes score ≤ 3.1. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.
Time frame: At Week 52
Substudy 3: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 52
The Inflammatory Bowel Disease Questionnaire (IBDQ) is used to assess health-related quality of life (HRQoL) in patients with ulcerative colitis. It consists of 32 questions evaluating bowel and systemic symptoms, as well as emotional and social functions. Each question is answered on a scale from 1 (worst) to 7 (best). The total score ranges from 32 to 224 with higher scores indicating better health-related quality of life. A positive change from Baseline indicates improvement.
Time frame: Baseline (Week 0), Week 52
Substudy 3: Percentage Of Participants With Mucosal Healing at Week 52
Mucosal healing is defined as an endoscopic score of 0 and Geboes score \< 2.0. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.
Time frame: At Week 52
Substudy 3: Percentage Of Participants Who Reported No Bowel Urgency at Week 52
Bowel urgency was assessed by participants in a subject diary completed once a day.
Time frame: At Week 52
Substudy 3: Percentage Of Participants Who Reported No Abdominal Pain at Week 52
Abdominal pain was assessed by participants in a subject diary completed once a day.
Time frame: At Week 52
Substudy 3: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 52
The FACIT fatigue questionnaire was developed to assess fatigue associated with anemia. It consists of 13 fatigue-related questions. Each question is answered on a 5-point Likert scale: 0 (not at all); 1 (a little bit); 2 (somewhat); 3 (quite a bit); and 4 (very much). The total score ranges from 0 to 52, where higher scores represent less fatigue, and a positive change from Baseline indicates improvement.
Time frame: Baseline (Week 0), Week 52
| Milestone | SS1: Placebo | SS1: Upadacitinib 7.5 mg | SS1: Upadacitinib 15 mg | SS1: Upadacitinib 30 mg | SS1: Upadacitinib 45 mg | SS2: Placebo/Upadacitinib 45 mg | SS2: Upadacitinib 45 mg/Upadacitinib 45 mg | SS3: M14-675 Clinical Responders | SS3: Placebo | SS3: UPA 7.5 mg | SS3: UPA 15 mg | SS3: UPA 30 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 46 | 47 | 49 | 117 | 123 | 155 | 319 | 446 | 0 | 0 | 0 | 0 |
| Completed | 41 | 45 | 45 | 105 | 113 | 135 | 306 | 446 | 0 | 0 | 0 | 0 |
| Not completed | 5 | 2 | 4 | 12 | 10 | 20 | 13 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 3 | 1 | 3 | 5 | 4 | 9 | 6 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 0 | 0 | 0 | 0 | 1 | 3 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Covid-19 logistical restrictions | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other, not specified | 2 | 1 | 1 | 7 | 5 | 7 | 3 | 0 | 0 | 0 | 0 | 0 |
| Milestone | SS1: Placebo | SS1: Upadacitinib 7.5 mg | SS1: Upadacitinib 15 mg | SS1: Upadacitinib 30 mg | SS1: Upadacitinib 45 mg | SS2: Placebo/Upadacitinib 45 mg | SS2: Upadacitinib 45 mg/Upadacitinib 45 mg | SS3: M14-675 Clinical Responders | SS3: Placebo | SS3: UPA 7.5 mg | SS3: UPA 15 mg | SS3: UPA 30 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 85 | 59 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 74 | 47 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 11 | 12 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Covid-19 logistical restrictions | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other, not specified | 0 | 0 | 0 | 0 | 0 | 4 | 8 | 0 | 0 | 0 | 0 | 0 |
| Milestone | SS1: Placebo | SS1: Upadacitinib 7.5 mg | SS1: Upadacitinib 15 mg | SS1: Upadacitinib 30 mg | SS1: Upadacitinib 45 mg | SS2: Placebo/Upadacitinib 45 mg | SS2: Upadacitinib 45 mg/Upadacitinib 45 mg | SS3: M14-675 Clinical Responders | SS3: Placebo | SS3: UPA 7.5 mg | SS3: UPA 15 mg | SS3: UPA 30 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 386 | 20 | 324 | 316 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 140 | 11 | 218 | 248 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 246 | 9 | 106 | 68 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32 | 3 | 12 | 18 |
| Withdrew: Withdrew consent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 1 | 4 | 9 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 |
| Withdrew: Covid-19 logistical restrictions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other, not specified | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 202 | 5 | 89 | 39 |
The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration) The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. For Substudy 1, clinical remission is defined as SFS ≤ 1, RBS of 0, and endoscopic subscore ≤ 1.
| percentage of participants | SS1: Placebo | SS1: Upadacitinib 7.5 mg | SS1: Upadacitinib 15 mg | SS1: Upadacitinib 30 mg | SS1: Upadacitinib 45 mg |
|---|---|---|---|---|---|
| Substudy 1: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 | 0 | 8.5 | 14.3 | 13.5 | 21.4 |
The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal) 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed) 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration) The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. For Substudy 2, clinical remission is defined as SFS ≤ 1 and not greater than Baseline, RBS of 0, and endoscopic subscore ≤ 1. In Substudy 2, evidence of friability during endoscopy in participants with otherwise "mild" endoscopic activity conferred an endoscopic subscore of 2.
| percentage of participants | SS2: Placebo | SS2: Upadacitinib 45 mg |
|---|---|---|
| Substudy 2: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 | 4.8 | 26.1 |
The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. For Substudy 3, clinical remission is defined as SFS ≤ 1 and not greater than Baseline, RBS of 0, and endoscopic subscore ≤ 1. In addition, evidence of friability during endoscopy in participants with otherwise "mild" endoscopic activity conferred an endoscopic subscore of 2.
| percentage of participants | SS3: Placebo | SS3: UPA 15 mg | SS3: UPA 30 mg |
|---|---|---|---|
| Substudy 3: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 52 | 12.1 (6.9 to 17.4) | 42.3 (34.3 to 50.3) | 51.7 (43.6 to 59.8) |
Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
| percentage of participants | SS1: Placebo | SS1: Upadacitinib 7.5 mg | SS1: Upadacitinib 15 mg | SS1: Upadacitinib 30 mg | SS1: Upadacitinib 45 mg |
|---|---|---|---|---|---|
| Substudy 1: Percentage Of Participants With Endoscopic Improvement at Week 8 | 2.2 | 14.9 | 30.6 | 26.9 | 35.7 |
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The Full Mayo score (FMS) ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.
| percentage of participants | SS1: Placebo | SS1: Upadacitinib 7.5 mg | SS1: Upadacitinib 15 mg | SS1: Upadacitinib 30 mg | SS1: Upadacitinib 45 mg |
|---|---|---|---|---|---|
| Substudy 1: Percentage Of Participants Achieving Clinical Remission Per Full Mayo Score at Week 8 | 0 | 10.6 | 10.2 | 11.5 | 19.6 |
The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. Clinical response is defined as a decrease from baseline in the Adapted Mayo score ≥ 2 points and ≥ 30% from baseline, and a decrease in RBS ≥ 1 or an absolute RBS ≤ 1).
| percentage of participants | SS1: Placebo | SS1: Upadacitinib 7.5 mg | SS1: Upadacitinib 15 mg | SS1: Upadacitinib 30 mg | SS1: Upadacitinib 45 mg |
|---|---|---|---|---|---|
| Substudy 1: Percentage Of Participants Achieving Clinical Response Per Adapted Mayo Score at Week 8 | 13.0 | 29.8 | 49.0 | 46.2 | 55.4 |
The Partial Mayo Score is a composite score of UC disease activity based on the following 2 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). The overall Partial Mayo score ranges from 0 to 6 with higher scores representing more severe disease. Clinical response per Partial Mayo Score is defined as a decrease in Partial Adapted Mayo score ≥ 2 points and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.
| percentage of participants | SS1: Placebo | SS1: Upadacitinib 7.5 mg | SS1: Upadacitinib 15 mg | SS1: Upadacitinib 30 mg | SS1: Upadacitinib 45 mg |
|---|---|---|---|---|---|
| Substudy 1: Percentage Of Participants Achieving Clinical Response Per Partial Mayo Score at Week 2 | 17.4 | 23.4 | 34.7 | 36.5 | 55.4 |
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The Full Mayo score (FMS) ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.
| units on a scale | SS1: Placebo | SS1: Upadacitinib 7.5 mg | SS1: Upadacitinib 15 mg | SS1: Upadacitinib 30 mg | SS1: Upadacitinib 45 mg |
|---|---|---|---|---|---|
| Substudy 1: Change in Full Mayo Score From Baseline to Week 8 | -0.741 ± 2.3302 | -2.870 ± 2.9685 | -3.589 ± 2.4984 | -4.211 ± 3.0886 | -4.606 ± 2.8976 |
Endoscopic remission is defined as an endoscopic subscore of 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
| percentage of participants | SS1: Placebo | SS1: Upadacitinib 7.5 mg | SS1: Upadacitinib 15 mg | SS1: Upadacitinib 30 mg | SS1: Upadacitinib 45 mg |
|---|---|---|---|---|---|
| Substudy 1: Percentage Of Participants With Endoscopic Remission at Week 8 | 0 | 6.4 | 4.1 | 9.6 | 17.9 |
The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration. Histologic improvement was defined as decrease from baseline in Geboes score.
| percentage of participants | SS1: Placebo | SS1: Upadacitinib 7.5 mg | SS1: Upadacitinib 15 mg | SS1: Upadacitinib 30 mg | SS1: Upadacitinib 45 mg |
|---|---|---|---|---|---|
| Substudy 1: Percentage Of Participants Who Achieved Histologic Improvement at Week 8 | 6.5 | 31.9 | 51.0 | 44.2 | 48.2 |
Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
| percentage of participants | SS2: Placebo | SS2: Upadacitinib 45 mg |
|---|---|---|
| Substudy 2: Percentage Of Participants With Endoscopic Improvement at Week 8 | 7.4 (3.2 to 11.5) | 36.3 (31.0 to 41.7) |
Endoscopic remission is defined as an endoscopic subscore of 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
| percentage of participants | SS2: Placebo | SS2: Upadacitinib 45 mg |
|---|---|---|
| Substudy 2: Percentage Of Participants With Endoscopic Remission at Week 8 | 1.3 (0.0 to 3.1) | 13.7 (9.9 to 17.6) |
The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. Clinical response is defined as a decrease from baseline in the Adapted Mayo score ≥ 2 points and ≥ 30% from baseline, and a decrease in RBS ≥ 1 or an absolute RBS ≤ 1).
| percentage of participants | SS2: Placebo | SS2: Upadacitinib 45 mg |
|---|---|---|
| Substudy 2: Percentage Of Participants Achieving Clinical Response Per Adapted Mayo Score at Week 8 | 27.3 (20.2 to 34.3) | 72.6 (67.7 to 77.5) |
The Partial Mayo Score is a composite score of UC disease activity based on the following 2 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). The overall Partial Mayo score ranges from 0 to 6 with higher scores representing more severe disease. Clinical response per Partial Mayo Score is defined as a decrease from Baseline ≥ 1 point and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.
| percentage of participants | SS2: Placebo | SS2: Upadacitinib 45 mg |
|---|---|---|
| Substudy 2: Percentage Of Participants Achieving Clinical Response Per Partial Mayo Score at Week 2 | 27.3 (20.2 to 34.3) | 60.1 (54.7 to 65.5) |
Histologic-endoscopic mucosal improvement is defined as an endoscopic subscore of 0 or 1 and a Geboes score ≤ 3.1. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.
| percentage of participants | SS2: Placebo | SS2: Upadacitinib 45 mg |
|---|---|---|
| Substudy 2: Percentage Of Participants Who Achieved Histologic-Endoscopic Mucosal Improvement at Week 8 | 6.6 (2.6 to 10.5) | 30.1 (25.0 to 35.1) |
Bowel urgency was assessed by participants in a subject diary completed once a day.
| percentage of participants | SS2: Placebo | SS2: Upadacitinib 45 mg |
|---|---|---|
| Substudy 2: Percentage Of Participants Who Report No Bowel Urgency at Week 8 | 21.4 (14.9 to 27.9) | 48.4 (42.9 to 53.9) |
Abdominal pain was assessed by participants in a subject diary completed once a day.
| percentage of participants | SS2: Placebo | SS2: Upadacitinib 45 mg |
|---|---|---|
| Substudy 2: Percentage Of Participants Who Reported No Abdominal Pain at Week 8 | 23.4 (16.7 to 30.1) | 46.6 (41.1 to 52.1) |
The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration. Histologic improvement was defined as decrease from baseline in Geboes score.
| percentage of participants | SS2: Placebo | SS2: Upadacitinib 45 mg |
|---|---|---|
| Substudy 2: Percentage Of Participants Who Achieved Histologic Improvement at Week 8 | 22.5 (15.9 to 29.1) | 55.0 (49.5 to 60.5) |
The Inflammatory Bowel Disease Questionnaire (IBDQ) is used to assess health-related quality of life (HRQoL) in patients with ulcerative colitis. It consists of 32 questions evaluating bowel and systemic symptoms, as well as emotional and social functions. Each question is answered on a scale from 1 (worst) to 7 (best). The total score ranges from 32 to 224 with higher scores indicating better health-related quality of life. A positive change from Baseline indicates improvement.
| units on a scale | SS2: Placebo | SS2: Upadacitinib 45 mg |
|---|---|---|
| Substudy 2: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 8 | 21.7 (16.03 to 27.28) | 55.3 (51.54 to 59.15) |
Mucosal healing is defined as an endoscopic score of 0 and Geboes score \< 2.0. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.
| percentage of participants | SS2: Placebo | SS2: Upadacitinib 45 mg |
|---|---|---|
| Substudy 2: Percentage Of Participants With Mucosal Healing at Week 8 | 1.3 (0.0 to 3.1) | 10.7 (7.3 to 14.1) |
The FACIT fatigue questionnaire was developed to assess fatigue associated with anemia. It consists of 13 fatigue-related questions. Each question is answered on a 5-point Likert scale: 0 (not at all); 1 (a little bit); 2 (somewhat); 3 (quite a bit); and 4 (very much). The total score ranges from 0 to 52, where higher scores represent less fatigue, and a positive change from Baseline indicates improvement.
| units on a scale | SS2: Placebo | SS2: Upadacitinib 45 mg |
|---|---|---|
| Substudy 2: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 8 | 2.8 (1.23 to 4.44) | 9.5 (8.44 to 10.61) |
Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
| percentage of participants | SS3: Placebo | SS3: UPA 15 mg | SS3: UPA 30 mg |
|---|---|---|---|
| Substudy 3: Percentage Of Participants With Endoscopic Improvement at Week 52 | 14.5 (8.7 to 20.3) | 48.7 (40.5 to 56.8) | 61.6 (53.6 to 69.6) |
The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. For Substudy 3, clinical remission is defined as SFS ≤ 1 and not greater than Baseline, RBS of 0, and endoscopic subscore ≤ 1. In addition, evidence of friability during endoscopy in participants with otherwise "mild" endoscopic activity conferred an endoscopic subscore of 2.
| percentage of participants | SS3: Placebo | SS3: UPA 15 mg | SS3: UPA 30 mg |
|---|---|---|---|
| Substudy 3: Percentage of Participants With Clinical Remission Per Adapted Mayo Score at Week 52 Among Those Who Achieved Clinical Remission at the End of the Induction Treatment | 22.2 (11.1 to 33.3) | 59.2 (45.1 to 73.4) | 69.7 (57.7 to 81.8) |
The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. For Substudy 3, clinical remission is defined as SFS ≤ 1 and not greater than Baseline, RBS of 0, and endoscopic subscore ≤ 1. In addition, evidence of friability during endoscopy in participants with otherwise "mild" endoscopic activity conferred an endoscopic subscore of 2.
| percentage of participants | SS3: Placebo | SS3: UPA 15 mg | SS3: UPA 30 mg |
|---|---|---|---|
| Substudy 3: Percentage of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Wk 52 and Were Corticosteroid Free for ≥ 90 Days Immediately Preceding Wk 52 Among Those Who Achieved Clinical Remission at the End of the Induction Treatment | 22.2 (11.1 to 33.3) | 57.1 (42.9 to 71.3) | 68.0 (55.8 to 80.2) |
Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
| percentage of participants | SS3: Placebo | SS3: UPA 15 mg | SS3: UPA 30 mg |
|---|---|---|---|
| Substudy 3: Percentage of Participants With Endoscopic Improvement at Wk 52 Among Those Who Achieved Endoscopic Improvement at the End of the Induction Treatment | 19.2 (9.9 to 28.4) | 61.6 (49.6 to 73.7) | 69.5 (59.1 to 80.0) |
Endoscopic remission is defined as an endoscopic subscore of 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
| percentage of participants | SS3: Placebo | SS3: UPA 15 mg | SS3: UPA 30 mg |
|---|---|---|---|
| Substudy 3: Percentage Of Participants With Endoscopic Remission At Week 52 | 5.6 (1.8 to 9.3) | 24.2 (17.3 to 31.2) | 25.9 (18.8 to 33.0) |
The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. Clinical response is defined as a decrease from baseline in the Adapted Mayo score ≥ 2 points and ≥ 30% from baseline, and a decrease in RBS ≥ 1 or an absolute RBS ≤ 1).
| percentage of participants | SS3: Placebo | SS3: UPA 15 mg | SS3: UPA 30 mg |
|---|---|---|---|
| Substudy 3: Percentage Of Participants Who Maintained Clinical Response Per Adapted Mayo Score at Wk 52 Among Those Who Achieved Clinical Response at the End of the Induction Treatment | 18.8 (12.1 to 25.5) | 63.0 (54.8 to 71.1) | 76.6 (69.6 to 83.6) |
Histologic-endoscopic mucosal improvement is defined as an endoscopic subscore of 0 or 1 and a Geboes score ≤ 3.1. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.
| percentage of participants | SS3: Placebo | SS3: UPA 15 mg | SS3: UPA 30 mg |
|---|---|---|---|
| Substudy 3: Percentage Of Participants Who Achieved Histologic-Endoscopic Mucosal Improvement at Week 52 | 11.9 (6.7 to 17.2) | 35.0 (27.1 to 42.8) | 49.8 (41.5 to 58.0) |
The Inflammatory Bowel Disease Questionnaire (IBDQ) is used to assess health-related quality of life (HRQoL) in patients with ulcerative colitis. It consists of 32 questions evaluating bowel and systemic symptoms, as well as emotional and social functions. Each question is answered on a scale from 1 (worst) to 7 (best). The total score ranges from 32 to 224 with higher scores indicating better health-related quality of life. A positive change from Baseline indicates improvement.
| units on a scale | SS3: Placebo | SS3: UPA 15 mg | SS3: UPA 30 mg |
|---|---|---|---|
| Substudy 3: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 52 | 17.9 (10.79 to 25.00) | 49.2 (42.59 to 55.89) | 58.9 (52.14 to 65.59) |
Mucosal healing is defined as an endoscopic score of 0 and Geboes score \< 2.0. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.
| percentage of participants | SS3: Placebo | SS3: UPA 15 mg | SS3: UPA 30 mg |
|---|---|---|---|
| Substudy 3: Percentage Of Participants With Mucosal Healing at Week 52 | 4.7 (1.3 to 8.2) | 17.6 (11.4 to 23.8) | 19.0 (12.6 to 25.4) |
Bowel urgency was assessed by participants in a subject diary completed once a day.
| percentage of participants | SS3: Placebo | SS3: UPA 15 mg | SS3: UPA 30 mg |
|---|---|---|---|
| Substudy 3: Percentage Of Participants Who Reported No Bowel Urgency at Week 52 | 17.4 (11.4 to 23.5) | 56.1 (48.1 to 64.1) | 63.6 (56.0 to 71.2) |
Abdominal pain was assessed by participants in a subject diary completed once a day.
| percentage of participants | SS3: Placebo | SS3: UPA 15 mg | SS3: UPA 30 mg |
|---|---|---|---|
| Substudy 3: Percentage Of Participants Who Reported No Abdominal Pain at Week 52 | 20.8 (14.2 to 27.3) | 45.9 (37.9 to 54.0) | 55.3 (47.4 to 63.2) |
The FACIT fatigue questionnaire was developed to assess fatigue associated with anemia. It consists of 13 fatigue-related questions. Each question is answered on a 5-point Likert scale: 0 (not at all); 1 (a little bit); 2 (somewhat); 3 (quite a bit); and 4 (very much). The total score ranges from 0 to 52, where higher scores represent less fatigue, and a positive change from Baseline indicates improvement.
| units on a scale | SS3: Placebo | SS3: UPA 15 mg | SS3: UPA 30 mg |
|---|---|---|---|
| Substudy 3: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 52 | 3.7 (1.88 to 5.43) | 8.7 (7.01 to 10.49) | 9.5 (7.80 to 11.22) |
Collected over All-cause mortality is reported from enrollment to end of study; median time on follow-up was up to 57, 61, and 364 days for Substudies 1, 2, and 3, respectively. TEAEs and SAEs were collected from first dose of study drug until 30 days after last dose of study drug; mean duration on study drug was up to 57, 56, and 364 days for Substudies 1, 2, and 3, respectively.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SS1: Placebo | 0/46 (0%) | 5/46 (10.9%) | 27/46 (58.7%) |
| SS1: Upadacitinib 7.5 mg | 0/47 (0%) | 0/47 (0%) | 18/47 (38.3%) |
| SS1: Upadacitinib 15 mg | 0/49 (0%) | 2/49 (4.1%) | 22/49 (44.9%) |
| SS1: Upadacitinib 30 mg | 0/117 (0%) | 5/117 (4.3%) | 58/117 (49.6%) |
| SS1: Upadacitinib 45 mg | 0/123 (0%) | 6/123 (4.9%) | 50/123 (40.7%) |
| SS2: Placebo | 0/155 (0%) | 9/155 (5.8%) | 62/155 (40%) |
| SS2: Upadacitinib 45 mg | 0/319 (0%) | 8/319 (2.5%) | 121/319 (37.9%) |
| SS2: Placebo/Upadacitinib 45 mg | 0/85 (0%) | 2/85 (2.4%) | 36/85 (42.4%) |
| SS2: Upadacitinib 45 mg/Upadacitinib 45 mg | 0/59 (0%) | 2/59 (3.4%) | 17/59 (28.8%) |
| SS3: Placebo | 0/385 (0%) | 32/385 (8.3%) | 216/385 (56.1%) |
| SS3: Upadacitinib 7.5 mg | 0/20 (0%) | 0/20 (0%) | 18/20 (90%) |
| SS3: Upadacitinib 15 mg | 0/323 (0%) | 24/323 (7.4%) | 181/323 (56%) |
| SS3: Upadacitinib 30 mg | 0/316 (0%) | 25/316 (7.9%) | 166/316 (52.5%) |
| Event | SS1: Placebo | SS1: Upadacitinib 7.5 mg | SS1: Upadacitinib 15 mg | SS1: Upadacitinib 30 mg | SS1: Upadacitinib 45 mg | SS2: Placebo | SS2: Upadacitinib 45 mg | SS2: Placebo/Upadacitinib 45 mg | SS2: Upadacitinib 45 mg/Upadacitinib 45 mg | SS3: Placebo | SS3: Upadacitinib 7.5 mg | SS3: Upadacitinib 15 mg | SS3: Upadacitinib 30 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COLITIS ULCERATIVEGastrointestinal disorders | 2/46 | 0/47 | 1/49 | 4/117 | 3/123 | 5/155 | 2/319 | 1/85 | 1/59 | 9/385 | 0/20 | 1/323 | 3/316 |
| ANAEMIABlood and lymphatic system disorders | 0/46 | 0/47 | 0/49 | 0/117 | 0/123 | 0/155 | 0/319 | 2/85 | 0/59 | 0/385 | 0/20 | 0/323 | 1/316 |
| CELLULITISInfections and infestations | 1/46 | 0/47 | 0/49 | 0/117 | 0/123 | 1/155 | 0/319 | 0/85 | 0/59 | 1/385 | 0/20 | 0/323 | 0/316 |
| SINUSITISInfections and infestations | 1/46 | 0/47 | 0/49 | 0/117 | 0/123 | 0/155 | 0/319 | 0/85 | 0/59 | 0/385 | 0/20 | 0/323 | 0/316 |
| HYPOPHOSPHATAEMIAMetabolism and nutrition disorders | 1/46 | 0/47 | 0/49 | 0/117 | 0/123 | 0/155 | 0/319 | 0/85 | 0/59 | 0/385 | 0/20 | 0/323 | 0/316 |
| UROSEPSISInfections and infestations | 0/46 | 0/47 | 1/49 | 0/117 | 0/123 | 0/155 | 0/319 | 0/85 | 0/59 | 0/385 | 0/20 | 0/323 | 0/316 |
| HYPOTENSIONVascular disorders | 0/46 | 0/47 | 0/49 | 0/117 | 0/123 | 0/155 | 0/319 | 0/85 | 1/59 | 0/385 | 0/20 | 0/323 | 0/316 |
| ILEUSGastrointestinal disorders | 0/46 | 0/47 | 0/49 | 1/117 | 0/123 | 0/155 | 0/319 | 0/85 | 0/59 | 0/385 | 0/20 | 0/323 | 0/316 |
| CYSTITIS HAEMORRHAGICRenal and urinary disorders | 0/46 | 0/47 | 0/49 | 1/117 | 0/123 | 0/155 | 0/319 | 0/85 | 0/59 | 0/385 | 0/20 | 0/323 | 0/316 |
| ABDOMINAL PAINGastrointestinal disorders | 0/46 | 0/47 | 0/49 | 0/117 | 1/123 | 0/155 | 0/319 | 0/85 | 0/59 | 0/385 | 0/20 | 0/323 | 0/316 |
| Event | SS1: Placebo | SS1: Upadacitinib 7.5 mg | SS1: Upadacitinib 15 mg | SS1: Upadacitinib 30 mg | SS1: Upadacitinib 45 mg | SS2: Placebo | SS2: Upadacitinib 45 mg | SS2: Placebo/Upadacitinib 45 mg | SS2: Upadacitinib 45 mg/Upadacitinib 45 mg | SS3: Placebo | SS3: Upadacitinib 7.5 mg | SS3: Upadacitinib 15 mg | SS3: Upadacitinib 30 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COLITIS ULCERATIVEGastrointestinal disorders | 4/46 | 1/47 | 2/49 | 4/117 | 3/123 | 16/155 | 1/319 | 2/85 | 1/59 | 101/385 | 3/20 | 40/323 | 24/316 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 1/46 | 2/47 | 0/49 | 2/117 | 3/123 | 7/155 | 5/319 | 0/85 | 0/59 | 28/385 | 4/20 | 19/323 | 8/316 |
| HEADACHENervous system disorders | 5/46 | 4/47 | 4/49 | 9/117 | 8/123 | 4/155 | 13/319 | 4/85 | 2/59 | 16/385 | 0/20 | 10/323 | 14/316 |
| CONSTIPATIONGastrointestinal disorders | 1/46 | 0/47 | 0/49 | 1/117 | 1/123 | 0/155 | 6/319 | 2/85 | 0/59 | 2/385 | 2/20 | 4/323 | 7/316 |
| DIARRHOEAGastrointestinal disorders | 0/46 | 0/47 | 0/49 | 0/117 | 2/123 | 0/155 | 1/319 | 0/85 | 0/59 | 4/385 | 2/20 | 2/323 | 2/316 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 0/46 | 1/47 | 4/49 | 3/117 | 6/123 | 6/155 | 8/319 | 0/85 | 0/59 | 11/385 | 2/20 | 19/323 | 15/316 |
| URINARY TRACT INFECTIONInfections and infestations | 0/46 | 1/47 | 0/49 | 3/117 | 1/123 | 3/155 | 3/319 | 2/85 | 0/59 | 9/385 | 2/20 | 10/323 | 4/316 |
| COUGHRespiratory, thoracic and mediastinal disorders | 1/46 | 1/47 | 1/49 | 3/117 | 4/123 | 2/155 | 5/319 | 2/85 | 1/59 | 6/385 | 2/20 | 6/323 | 4/316 |
| RASHSkin and subcutaneous tissue disorders | 0/46 | 1/47 | 0/49 | 5/117 | 1/123 | 1/155 | 8/319 | 0/85 | 1/59 | 14/385 | 2/20 | 9/323 | 14/316 |
| NASOPHARYNGITISInfections and infestations | 3/46 | 1/47 | 3/49 | 3/117 | 4/123 | 6/155 | 15/319 | 4/85 | 1/59 | 27/385 | 0/20 | 31/323 | 30/316 |
Intent-to-treat (ITT) analysis set: Substudy 1 (all randomized participants who received at least one dose of study drug in Substudy 1); Substudy 2 (all randomized participants who received at least one dose of doubleblinded study drug in Part 1 and all participants who received at least one dose of upadacitinib 45 mg in Part 2); Substudy 3 (all M14-675 participants who received at least one dose of study drug in Substudy 3)
| Age, Continuous(years) | SS1: Placebo | SS1: Upadacitinib 7.5 mg | SS1: Upadacitinib 15 mg | SS1: Upadacitinib 30 mg | SS1: Upadacitinib 45 mg | SS2: Placebo/Upadacitinib 45 mg | SS2: Upadacitinib 45 mg/Upadacitinib 45 mg | SS3: M14-675 Clinical Responders | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 42.3 ± 13.29 | 41.7 ± 14.58 | 46.0 ± 13.58 | 42.9 ± 14.44 | 41.6 ± 14.19 | 44.3 ± 14.64 | 43.6 ± 14.04 | 42.1 ± 14.42 | 42.9 ± 14.27 |
| Sex: Female, Male(Participants) | SS1: Placebo | SS1: Upadacitinib 7.5 mg | SS1: Upadacitinib 15 mg | SS1: Upadacitinib 30 mg | SS1: Upadacitinib 45 mg | SS2: Placebo/Upadacitinib 45 mg | SS2: Upadacitinib 45 mg/Upadacitinib 45 mg | SS3: M14-675 Clinical Responders | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 17 | 24 | 19 | 47 | 44 | 58 | 121 | 170 | 500 |
| Male | 29 | 23 | 30 | 70 | 79 | 97 | 198 | 276 | 802 |
| Race/Ethnicity, Customized(Participants) | SS1: Placebo | SS1: Upadacitinib 7.5 mg | SS1: Upadacitinib 15 mg | SS1: Upadacitinib 30 mg | SS1: Upadacitinib 45 mg | SS2: Placebo/Upadacitinib 45 mg | SS2: Upadacitinib 45 mg/Upadacitinib 45 mg | SS3: M14-675 Clinical Responders | Total |
|---|---|---|---|---|---|---|---|---|---|
| White | 37 | 36 | 38 | 88 | 90 | 101 | 206 | 302 | 898 |
| Black or African American | 0 | 3 | 1 | 3 | 2 | 4 | 12 | 15 | 40 |
| Asian | 8 | 7 | 10 | 23 | 28 | 46 | 95 | 124 | 341 |
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Multiple | 1 | 1 | 0 | 2 | 3 | 2 | 5 | 3 | 17 |
| Average Stool Frequency Subscore(units on a scale) | SS1: Placebo | SS1: Upadacitinib 7.5 mg | SS1: Upadacitinib 15 mg | SS1: Upadacitinib 30 mg | SS1: Upadacitinib 45 mg | SS2: Placebo/Upadacitinib 45 mg | SS2: Upadacitinib 45 mg/Upadacitinib 45 mg | SS3: M14-675 Clinical Responders | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 2.56 ± 0.667 | 2.62 ± 0.600 | 2.68 ± 0.565 | 2.61 ± 0.613 | 2.58 ± 0.648 | 2.52 ± 0.668 | 2.60 ± 0.624 | 2.55 ± 0.623 | 2.58 ± 0.628 |
| Average Rectal Bleeding Subscore(units on a scale) | SS1: Placebo | SS1: Upadacitinib 7.5 mg | SS1: Upadacitinib 15 mg | SS1: Upadacitinib 30 mg | SS1: Upadacitinib 45 mg | SS2: Placebo/Upadacitinib 45 mg | SS2: Upadacitinib 45 mg/Upadacitinib 45 mg | SS3: M14-675 Clinical Responders | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 1.66 ± 1.034 | 1.61 ± 1.027 | 1.55 ± 0.915 | 1.51 ± 0.975 | 1.49 ± 0.960 | 1.76 ± 0.994 | 1.71 ± 1.046 | 1.77 ± 0.990 | 1.68 ± 1.003 |
| Average Endoscopy Subscore(units on a scale) | SS1: Placebo | SS1: Upadacitinib 7.5 mg | SS1: Upadacitinib 15 mg | SS1: Upadacitinib 30 mg | SS1: Upadacitinib 45 mg | SS2: Placebo/Upadacitinib 45 mg | SS2: Upadacitinib 45 mg/Upadacitinib 45 mg | SS3: M14-675 Clinical Responders | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 2.8 ± 0.43 | 2.8 ± 0.40 | 2.8 ± 0.39 | 2.7 ± 0.47 | 2.7 ± 0.48 | 2.7 ± 0.47 | 2.7 ± 0.46 | 2.7 ± 0.47 | 2.7 ± 0.46 |
| Previous Biologic Use(Participants) | SS1: Placebo | SS1: Upadacitinib 7.5 mg | SS1: Upadacitinib 15 mg | SS1: Upadacitinib 30 mg | SS1: Upadacitinib 45 mg | SS2: Placebo/Upadacitinib 45 mg | SS2: Upadacitinib 45 mg/Upadacitinib 45 mg | SS3: M14-675 Clinical Responders | Total |
|---|---|---|---|---|---|---|---|---|---|
| Yes | 35 | 36 | 38 | 87 | 92 | — | — | — | 288 |
| No | 11 | 11 | 11 | 30 | 31 | — | — | — | 94 |
| Biologic-inadequate Responder (Bio-IR) Status(Participants) | SS1: Placebo | SS1: Upadacitinib 7.5 mg | SS1: Upadacitinib 15 mg | SS1: Upadacitinib 30 mg | SS1: Upadacitinib 45 mg | SS2: Placebo/Upadacitinib 45 mg | SS2: Upadacitinib 45 mg/Upadacitinib 45 mg | SS3: M14-675 Clinical Responders | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bio-IR | — | — | — | — | — | 79 | 168 | 221 | 468 |
| Non-Bio-IR | — | — | — | — | — | 76 | 151 | 225 | 452 |
1 further baseline measures are reported on the registry.
Showing the first 100 of 496 sites across 46 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing, please refer to the link below.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · vivli.org
Ran from Sep 2016 to primary completion in Dec 2021, 62 months.
Results were first posted in Jun 2022, 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Upadacitinib